These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 15806191)

  • 1. COX-2 inhibitors--second, do some good.
    Harrison A
    N Z Med J; 2005 Apr; 118(1212):U1395. PubMed ID: 15806191
    [No Abstract]   [Full Text] [Related]  

  • 2. COX-2 inhibitors--first, do no harm.
    Weatherall M; Aldington S; Shirtcliffe P; Caldwell B; Beasley R
    N Z Med J; 2005 Mar; 118(1211):U1359. PubMed ID: 15778758
    [No Abstract]   [Full Text] [Related]  

  • 3. [New evaluation by the EU approval committee. Benefits of cox-2 inhibitors outweigh possible risks (interview by Dr. Thomas Meissner)].
    Brune K
    MMW Fortschr Med; 2004 Feb; 146(9):47. PubMed ID: 15352709
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular risk and COX-2 inhibition in rheumatological practice.
    Justice E; Carruthers DM
    J Hum Hypertens; 2005 Jan; 19(1):1-5. PubMed ID: 15385947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Celecoxib and cardiovascular risks.
    Brophy JM
    Expert Opin Drug Saf; 2005 Nov; 4(6):1005-15. PubMed ID: 16255660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COX-2 selective drugs and cardiovascular risks: same data but discrepant conclusions?
    Bannwarth B
    Expert Opin Drug Saf; 2006 Jan; 5(1):1-2; author reply 1-2. PubMed ID: 16370948
    [No Abstract]   [Full Text] [Related]  

  • 7. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR; Heerdink ER; de Boer A; van Dijk L; Leufkens HG
    Pharmacoepidemiol Drug Saf; 2005 Jul; 14(7):437-41. PubMed ID: 15937867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse cardiovascular effects of the coxibs.
    Dogné JM; Supuran CT; Pratico D
    J Med Chem; 2005 Apr; 48(7):2251-7. PubMed ID: 15801815
    [No Abstract]   [Full Text] [Related]  

  • 9. Precaution, cyclooxygenase inhibition, and cardiovascular risk.
    Ritter JM; Harding I; Warren JB
    Trends Pharmacol Sci; 2009 Oct; 30(10):503-8. PubMed ID: 19762092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of perioperative COX-2-inhibitor treatment: is a systematic review appropriate?
    Kehlet H
    N Z Med J; 2006 Jan; 119(1228):U1836. PubMed ID: 16462937
    [No Abstract]   [Full Text] [Related]  

  • 11. Cox-2 inhibitors: still no decisive action.
    Prescrire Int; 2005 Jun; 14(77):102. PubMed ID: 15981408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug insight: cyclo-oxygenase-2 inhibitors--a critical appraisal.
    Hinz B; Renner B; Brune K
    Nat Clin Pract Rheumatol; 2007 Oct; 3(10):552-60; quiz 1 p following 589. PubMed ID: 17906610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The practice implications of cardiovascular risks in NSAIDs.
    Hainsworth T
    Nurs Times; 2005 Jun 28-Jul 4; 101(26):26-7. PubMed ID: 16010838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Overestimated].
    Höer A; Häussler B
    Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
    [No Abstract]   [Full Text] [Related]  

  • 15. [COX 2 inhibitors--a further step back].
    Slørdal L; Evensen S; Spigset O
    Tidsskr Nor Laegeforen; 2005 Apr; 125(8):1046. PubMed ID: 15852094
    [No Abstract]   [Full Text] [Related]  

  • 16. [COX-2 inhibitors and cardiovascular adverse effects].
    Harg P; Madsen S
    Tidsskr Nor Laegeforen; 2001 Nov; 121(27):3190. PubMed ID: 11876144
    [No Abstract]   [Full Text] [Related]  

  • 17. [Recommendations for treatment with nonsteroidal anti-inflammatory drugs].
    Bolten WW
    MMW Fortschr Med; 2005 Aug; 147(31-32):24-7. PubMed ID: 16128192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A step back or training pain?].
    Raeder J
    Tidsskr Nor Laegeforen; 2005 Aug; 125(15):2050-1. PubMed ID: 16100553
    [No Abstract]   [Full Text] [Related]  

  • 19. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs.
    Mitchell JA; Warner TD
    Nat Rev Drug Discov; 2006 Jan; 5(1):75-86. PubMed ID: 16485347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COX-2 selective nonsteroidal anti-inflammatory drugs: current status.
    Mahajan A; Sharma R
    J Assoc Physicians India; 2005 Mar; 53():200-4. PubMed ID: 15926604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.